According to estimates from the World Health Organization (WHO), there will be 18.1 million new cases and 9.6 million cancer deaths worldwide in 2018. Cancer is a serious disease that affects people ...
Dual-target CAR T-cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), ...
The immune system is fast when it comes to fighting viruses, bacteria and other pathogens. But it also has to know when not to attack - for example, harmless substances such as pollen or house dust, ...
Lower regulatory T cells (Tregs) at diagnosis in patients with multiple myeloma were linked to early relapse and may indicate functional high-risk status (FHR). FHR patients experience aggressive ...
Coya Therapeutics, Inc. (NASDAQ: COYA) ("Coya" or the "Company"), a clinical-stage biotechnology company developing biologics ...
With insights into a molecular pathway that regulates the activity of Tregs, a type of T cell involved in immunosuppression, new research opens up possibly new avenues for treating inflammatory and ...
Regulatory T cells, Tregs (pronounced "T" "regs") for short, represent a divisive type of immune cell that can elicit beneficial but also harmful effects. As their name suggests, Tregs regulate the ...
Expression of co-inhibitory receptors or “checkpoint” molecules, such as CTLA-4 and PD-1, on effector T cells is a key mechanism for ensuring immune homeostasis. Dysregulated expression of ...
Tregs are ideal candidates for tolerance induction in the clinical context of solid organ and alloHSCT and may represent an ideal tool for an adoptive cellular therapy for inducing tolerance, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results